Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Asset Writedowns and Impairment (2016 - 2021)

Historic Asset Writedowns and Impairment for Altimmune (ALT) over the last 5 years, with Q4 2021 value amounting to $3.3 million.

  • Altimmune's Asset Writedowns and Impairment changed N/A to $3.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $11.4 million, marking a year-over-year change of. This contributed to the annual value of $12.4 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Altimmune reported Asset Writedowns and Impairment of $3.3 million as of Q4 2021.
  • In the past 5 years, Altimmune's Asset Writedowns and Impairment registered a high of $24.5 million during Q4 2018, and its lowest value of $490676.0 during Q1 2018.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $3.3 million (2021), whereas its average is $7.5 million.